MagForce

DGAP-News: MagForce AG Announces Financial Results for the Fiscal Year 2021 and Operational Highlights

Retrieved on: 
Thursday, June 30, 2022

In late 2021, MagForce USA obtained FDA approval to utilize the commercial protocol for the ongoing clinical trial.

Key Points: 
  • In late 2021, MagForce USA obtained FDA approval to utilize the commercial protocol for the ongoing clinical trial.
  • Based on these new developments, MagForce USA will be in a stronger financial position to complete the transition to the market.
  • MagForce, NanoTherm, NanoPlan, and NanoActivator are trademarks of MagForce AG in selected countries.
  • The results actually achieved by MagForce AG may substantially differ from these forward-looking statements.

DGAP-News: Coreo AG publishes consolidated figures (IFRS) for 2021

Retrieved on: 
Wednesday, May 11, 2022

Frankfurt am Main, 11 May 2022 - The Coreo Group can look back on a successful Financial Year 2021.

Key Points: 
  • Frankfurt am Main, 11 May 2022 - The Coreo Group can look back on a successful Financial Year 2021.
  • The EBIT rose by TEUR 3,528 from TEUR -690 to TEUR 2,838 compared to the previous year.
  • As in the past, the Managing Board will continue to focus on the growth of Coreo AG.
  • Coreo AG, with headquarters in Frankfurt am Main, is a dynamically growing real estate company with a focus on German commercial and residential real estate.

DGAP-News: MagForce AG: MagForce USA, Inc. receives Payment Code Approval by the American Medical Association for the Focal Ablation of Prostate Cancer with the NanoTherm Therapy System

Retrieved on: 
Tuesday, April 12, 2022

The payment codes will be programmed into the claims processing software of all payers and, thus, be fully implemented effective January 1, 2023.

Key Points: 
  • The payment codes will be programmed into the claims processing software of all payers and, thus, be fully implemented effective January 1, 2023.
  • "Our CPT code application for the NanoTherm Therapy system represented a first significant step in our preprations for commercialization.
  • AMA's approval of the new codes is the starting point for securing insurer reimbursement of our NanoTherm prostate ablation procedure.
  • MagForce AG assumes no obligation to update these forward-looking statements or to correct them in case of developments, which differ from those, anticipated.

DGAP-News: MagForce AG: Enrollment in Stage 2b of Pivotal U.S. Study for the Focal Ablation of Prostate Cancer with the NanoTherm Therapy System successfully underway following IRB approval

Retrieved on: 
Monday, December 20, 2021

MagForce AG: Enrollment in Stage 2b of Pivotal U.S. Study for the Focal Ablation of Prostate Cancer with the NanoTherm Therapy System successfully underway following IRB approval

Key Points: 
  • MagForce AG: Enrollment in Stage 2b of Pivotal U.S. Study for the Focal Ablation of Prostate Cancer with the NanoTherm Therapy System successfully underway following IRB approval
    The issuer is solely responsible for the content of this announcement.
  • After IRB approval, MagForce has now enrolled the first patients into the clinical trial while continuing to reach out to pre-identified potential study participants for updated testing and preparations.
  • "We are happy that enrollment in Stage 2b of our pivotal US study has successfully commenced and that the recruitment process is progressing well, despite once again surging Covid-19 cases.
  • The trial is designed to demonstrate that the NanoTherm therapy system can focally ablate targeted prostate cancer lesions with minimal side effects.

DGAP-News: MagForce AG: MagForce USA, Inc. has Received FDA's Approval to Proceed with Stage 2B with the Final Protocol of the Pivotal U.S. Study for the Focal Ablation of Prostate Cancer with the NanoTherm Ther

Retrieved on: 
Friday, November 5, 2021

Patient screening procedures, and enrollment of eligible patients, as well as treatments are being expedited at MagForce's NanoTherm treatment centers.

Key Points: 
  • Patient screening procedures, and enrollment of eligible patients, as well as treatments are being expedited at MagForce's NanoTherm treatment centers.
  • "We are very pleased that the FDA has greenlighted the final clinical trial protocol and we can now commence with Stage 2b of our pivotal US study.
  • The Stage 2b of the single-arm pivotal study is planned to evaluate the use of NanoTherm ablation for the treatment of prostate cancer patients with intermediate grade lesions.
  • The trial is designed to demonstrate that the NanoTherm therapy system can focally ablate targeted prostate cancer lesions with minimal side effects.

DGAP-News: MagForce AG Publishes Financial Results for H1/2021 and Operative Highlights

Retrieved on: 
Thursday, October 28, 2021

Following the Stage 2a results, MagForce submitted the clinical protocol for Stage 2b to the FDA.

Key Points: 
  • Following the Stage 2a results, MagForce submitted the clinical protocol for Stage 2b to the FDA.
  • MagForce AG closed the six-month period ended June 30, 2021, with a net loss of EUR - 5,054 thousand (previous year: EUR - 4,877 thousand).
  • About MagForce AG and MagForce USA, Inc.
    MagForce AG, listed in the Scale segment of the Frankfurt Stock Exchange (MF6, ISIN: DE000A0HGQF5), together with its subsidiary MagForce USA, Inc., is a leading medical device company in the field of nanomedicine focused on oncology.
  • MagForce, NanoTherm, NanoPlan, and NanoActivator are trademarks of MagForce AG in selected countries.

DGAP-News: MagForce AG: MagForce USA, Inc. has Received FDA's Conditions for Approval of the Final Protocol of the Pivotal U.S. Study for the Focal Ablation of Prostate Cancer with the NanoTherm Therapy System

Retrieved on: 
Wednesday, October 13, 2021

MagForce AG: MagForce USA, Inc. has Received FDA's Conditions for Approval of the Final Protocol of the Pivotal U.S. Study for the Focal Ablation of Prostate Cancer with the NanoTherm Therapy System

Key Points: 
  • MagForce AG: MagForce USA, Inc. has Received FDA's Conditions for Approval of the Final Protocol of the Pivotal U.S. Study for the Focal Ablation of Prostate Cancer with the NanoTherm Therapy System
    The issuer is solely responsible for the content of this announcement.
  • MagForce is pleased that the FDA's conditions include using the final protocol in Stage 2b with targeted biopsy to assess effectiveness.
  • MagForce believes the FDA conditions are reasonable, and files the necessary documentation with the authority.
  • The trial is designed to demonstrate that the NanoTherm therapy system can focally ablate targeted prostate cancer lesions with minimal side effects.

DGAP-News: MagForce AG and CHIP Hospital Málaga Announce Collaboration Agreement for the Commercial Treatment of Glioblastoma Cancer Patients with the NanoTherm Therapy System in Spain agForce AG:

Retrieved on: 
Thursday, September 30, 2021

MagForce AG and CHIP Hospital Mlaga Announce Collaboration Agreement for the Commercial Treatment of Glioblastoma Cancer Patients with the NanoTherm Therapy System in Spain agForce AG:

Key Points: 
  • MagForce AG and CHIP Hospital Mlaga Announce Collaboration Agreement for the Commercial Treatment of Glioblastoma Cancer Patients with the NanoTherm Therapy System in Spain agForce AG:
    The issuer is solely responsible for the content of this announcement.
  • CHIP Hospital performs more than 7,800 operations a year at its facilities, most part of them as partners of Carlos Haya Regional Hospital, in Mlaga.
  • We are proud to offer NanoTherm therapy in Mlaga, as the first hospital in Spain to do so, and thereby give our patients access to this state-of-the-art treatment option."
  • In addition to the collaboration for commercial treatments, an investigator-initiated trial (IIT) is planned with the NanoTherm therapy system at Carlos Haya University Hospital Mlaga.

DGAP-News: MagForce AG announces results of 2021 Annual General Meeting and changes to the Supervisory Board

Retrieved on: 
Thursday, August 12, 2021

Berlin, Germany, and Nevada, USA, August 12, 2021 - MagForce AG (Frankfurt, Scale, Xetra: MF6, ISIN: DE000A0HGQF5), a leading medical device company in the field of nanomedicine focused on oncology, today announced the results of the 2021 Annual General Meeting (AGM).

Key Points: 
  • Berlin, Germany, and Nevada, USA, August 12, 2021 - MagForce AG (Frankfurt, Scale, Xetra: MF6, ISIN: DE000A0HGQF5), a leading medical device company in the field of nanomedicine focused on oncology, today announced the results of the 2021 Annual General Meeting (AGM).
  • The Annual General Meeting approved resolution items 2 to 5 as well as 7, 8 and 10 - most of them with a significant majority.
  • Norbert Neef, Chairman of the Supervisory Board, informed the Annual General Meeting that he resigns from office effective as of the end of the AGM.
  • The Supervisory Board of MagForce AG, which also includes Klemens Hallmann and Aaron Weaver, will hold a constituent meeting shortly to vote on the new chair.

DGAP-News: MagForce AG Publishes Financial Results for the Year 2020 and Operative Highlights

Retrieved on: 
Wednesday, June 30, 2021

As a result, and as for numerous other indications, MagForce saw lower treatment numbers throughout the last ten months of 2020.

Key Points: 
  • As a result, and as for numerous other indications, MagForce saw lower treatment numbers throughout the last ten months of 2020.
  • By 2022, MagForce plans to have eight brain cancer treatment centers offering NanoTherm treatment for glioblastoma in Europe.
  • The FDA is reviewing MagForce USA's results from Stage 2a, which are consistent with what MagForce expected previously.
  • MagForce, NanoTherm, NanoPlan, and NanoActivator are trademarks of MagForce AG in selected countries.